Concurrent chemoradiotherapy with cisplatin and docetaxel for advanced head and neck cancer. A phase I study

Keyphrases

• Head-and-neck Cancer 100%
• Cisplatin 100%
• Concurrent Chemoradiotherapy 100%
• Docetaxel 100%
• Phase I Study 100%
• CDDP 66%
• Treatment Modalities 33%
• Maximum Tolerated Dose 33%
• Phase II Study 33%
• Hematotoxicity 33%
• Promising Treatment 33%
• Total Dose 33%
• Dose Level 33%
• Complete Response Rate 33%
• Dose-limiting Toxicity 33%
• Recommended Dose 33%
• Locoregionally Advanced 33%
• Conventionally Fractionated Radiotherapy 33%
• Lymphocytopenia 33%
• Low-dose Administration 33%
• Mucosal Toxicity 33%
• Mucositis 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemoradiation Therapy 100%
• Head and Neck Cancer 100%
• Cisplatin 100%
• Docetaxel 100%
• Lymphocytopenia 33%
• Maximum Tolerated Dose 33%
• Mucosa Inflammation 33%